spacer
home > ebr > spring 2019 > accessing difficult-to- synthesise metabolites in drug development programmes
PUBLICATIONS
European Biopharmaceutical Review

Accessing Difficult-to- Synthesise Metabolites in Drug Development Programmes

Access to major and/or disproportionate metabolites as part of drug development programmes is critical to ensure adherence to regulatory guidelines issued by the EMA and FDA, as well as to comply with internal safety standards within pharmaceutical companies themselves (1-2).

Identification and characterisation of metabolites ensures not only rigorous safety evaluation of significant metabolites, but can also expand patent coverage and reveal superior potency, reduced side effects, or improved physical properties compared to the parent drug.

Multiple options are available for making metabolites through both chemical and biological routes, as discussed by scientists at Abbvie (3) and summarised in Figure 1.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Julia Shanu-Wilson has over 25 years’ experience in the biotechnology and drug discovery industries. Following a BSc and PhD in microbial biochemistry at Imperial College London, UK, Julia worked in the biotech and pharma industries holding research leadership positions with Xenova, Cubist Pharmaceuticals, and TMO. She joined Hypha Discovery in 2013 and is on the management team, leading scientific communications for the company.
spacer
Julia Shanu-Wilson
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Registration Opens for Inaugural HPAPI USA Conference in October

The HPAPI global market is growing at an ever-increasing rate of CAGR at 8.6% that is projected to reach USD $31.56 Billion by 2025, with a significant segment market of HPAPI being oncology ADC which is at a CARG of a staggering 20%. The continual elevation of HPAPI potencies along with toxicity will further drive the needs for more cutting-edge containment solutions and best practices guidelines to ensure workers safety.
More info >>

White Papers

Personalised Medicine - Pharma and Dx Firms Share Wider Horizons

DiagnostikNet-BB

Personalised medicine might be a popular catch-phrase at the moment, but the term often causes confusion, as there is still no uniform definition for it. The expression can include areas as diverse as the measurement of individual risk, early detection using biomarker testing, stratification of patients suffering from a disease and predictions about its course.
More info >>

 
Industry Events

Nordic Life Science Days 10/12 September 2019

10-12 September 2019, Malmo Sweden

Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry. Bringing together the best talents in Life Science, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends. Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement